Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 16, 2014

Sun Pharma Nabs Injectable Drug CMO Pharmalucence

  • A subsidiary of Sun Pharmaceutical Industries has acquired New England-based firm Pharmalucence, which manufactures human injectable pharmaceuticals. Sun says Pharmalucence has sterile injectable capacity in the U.S., supported by strong R&D capabilities.

    Pharmalucence says it provides contract and private label formulation development and manufacturing services of noncytotoxic human injectables in either liquid or lyophilized form. According to the company's website, Pharmalucence has a 70,000 sq. ft. facility it claims to be New England's first CMO to use fully automated and isolated aseptic technology in support of customer needs ranging from small clinical fills to full commercial scale production.

    This has been an eventful year for the Indian generics manufacturer as in April Sun Pharma picked up fellow generics firm Ranbaxy Laboratories for $4 billion, with the aim of creating the world’s fifth-largest generic drug company. Also, in May, Sun Pharma closed down its Detroit facility run by Caraco Pharmaceutical Laboratories, of which Sun Pharma is a majority owner. The FDA shut down this facility in 2009 for failing to meet cGMP requirements; the facility reopened in August of 2012.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »